Synonyms:
(2R,3R,11BR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl l-valinate;
NBI-98854;
L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester;L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester;
Valbenazine [USAN:INN];
L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester;
L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester;
Valbenazine (USAN/INN);
GTPL8694;
CHEMBL2364639;
SCHEMBL15932979;
GEJDGVNQKABXKG-CFKGEZKQSA-N;
EX-A2002;
valbenazine;
MFCD28963976;
ZINC43195697;
CS-5908;
DB11915;
SB17456;
Valbenazine pound NBI-98854 pound(c);
AS-35294;
HY-16771;
D10675;
NBI-98854;NBI98854;NBI 98854;
valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester;
(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate;
(2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate;
(S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester;
[(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate;
Valbenazine tosylate;
Valbenazine [USAN];
Valbenazine ditosylate;
NBI-98854;
D0IX1I;
NBI-98782;
Valbenazine;
VMAT-2 inhibitor (CNS disease), Neurocrine;
Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine;
1025504-45-3;
Ingrezza;
UNII-54K37P50KH;
NBI 98854;
54K37P50KH;
Keywords: 1025504-45-3,MFCD28963976,1P000862,L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester,C24H38N2O4